Cerrato E, Echavarría-Pinto M, Tandjung K, Macaya C, Escaned J
Cardiovascular Institute, Hospital Clínico San Carlos, Faculty of Medicine Complutense UniversityMadrid, Spain -
Minerva Cardioangiol. 2014 Oct;62(5):407-20.
The introduction of coronary drug eluting stents (DES) more than 10 years ago drastically decreased the occurrence of restenosis, compared with first generation bare metal stents (BMS). However, the optimism created by the first studies was soon shadowed by the demonstration of higher rates of late and very late stent thrombosis (ST). The research performed in this phenomenon highlighted the causative role played by incomplete stent strut coverage, hypersensitivity reactions caused by the drug eluting polymer, and neoatherosclerosis, all markers of an inadequate vascular response to DES implantation. Over the following years, new development in stent and eluting polymer technologies have been incorporated in second generation DES to optimize the process of vessel healing and, thus, to avoid these complications. Furthermore, it is envisaged that adequate vessel healing would be followed by less dependence on double antiplatelet, a limiting aspect for DES use in different clinical scenarios. In this review, we focused on the use of biodegradable eluting polymers to increase DES safety, revisiting the rationale for its use and the synergic action with other changes in stent technology aimed to optimize vessel healing after DES implantation.
十多年前,与第一代裸金属支架(BMS)相比,冠状动脉药物洗脱支架(DES)的引入大幅降低了再狭窄的发生率。然而,最初研究带来的乐观情绪很快被更高的晚期和极晚期支架血栓形成(ST)发生率所掩盖。针对这一现象开展的研究突出了支架小梁覆盖不全、药物洗脱聚合物引起的超敏反应以及新生动脉粥样硬化所起的致病作用,这些都是血管对DES植入反应不足的标志。在接下来的几年里,支架和洗脱聚合物技术的新进展已被纳入第二代DES中,以优化血管愈合过程,从而避免这些并发症。此外,可以设想,充分的血管愈合将减少对双联抗血小板治疗的依赖,这是DES在不同临床场景中使用的一个限制因素。在这篇综述中,我们重点关注了使用可生物降解洗脱聚合物来提高DES的安全性,重新审视了其使用的基本原理以及与支架技术其他变化的协同作用,旨在优化DES植入后的血管愈合。